Mark G. Kris, MD, discusses treatment options for <em>MET</em>-mutant non–small cell lung cancer.
Mark G. Kris, MD, the William and Joy Ruane Chair in Thoracic Oncology in Memorial Sloan Kettering Cancer Center, discusses treatment options forMET-mutant nonsmall cell lung cancer (NSCLC).
Evidence shows that patients with high levels ofMETamplification can be treated with drugs that target the MET kinase. The occurrence ofMETis common in the smoking patient population. The Memorial Sloan Kettering Cancer Center, according to Kris, sees as manyMETmutations asALKalterations. Kris suggests performing next-generation sequencing on every patient with NSCLC upon diagnosis to findMETmutations among other biomarkers.
There are a few drugs available that are effective in treatingMET-mutant NSCLC. Currently, the standard of care is crizotinib (Xalkori), but preliminary research shows that other drugs, including capmatinib, savolitinib, and tepotinib, have better degrees of benefit and tolerability compared with crizotinib. Kris believes these drugs will eventually be approved by the FDA and become the new standards of care for patients withMET
Repotrectinib Elicits an Intracranial Response in ROS1+ Advanced NSCLC
March 25th 2024During a Case-Based Roundtable® event, Christine, Bestvina, MD, discussed the intracranial responses to repotrectinib for patients with ROS1-psotive non–small cell lung cancer in the first article of a 2-part series.
Read More
Ixabepilone/Bevacizumab Improves PFS and OS in Platinum-Resistant/Refractory Ovarian Cancer
March 19th 2024Combining ixabepilone with bevacizumab generated improved survival rates and high response rates compared with ixabepilone monotherapy in platinum-resistant or platinum-refractory ovarian cancer.
Read More